FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912784612> ?p ?o ?g. }

• W2912784612 endingPage "1207" @default.
• W2912784612 startingPage "1202" @default.
• W2912784612 abstract "In a population with atherosclerotic cardiovascular disease, previous research indicated that approximately 86% can achieve low-density lipoprotein cholesterol (LDL-C) of <70 mg/dL with oral lipid-lowering therapies (LLT) only, whereas 14% would require a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. We aim to estimate these values accounting for varying levels of statin intolerance. A simulation model described previously was used to estimate the utilization of LLT needed to achieve LDL-C <70 mg/dL via an intensification algorithm which maximized statins before adding ezetimibe or a PCSK9 inhibitor. The current analysis took into account varying background rates of statin intolerance. We defined statin intolerance as either partial (inability to tolerate high-intensity statin) or full (inability to tolerate any statin). With treatment intensification and 10% of patients having partial statin intolerance, the use of ezetimibe (± statin ± PCSK9 inhibitor) increased from 32.7% to 34.9%, and the need for a PCSK9 inhibitor (+ ezetimibe ± statin) increased from 14.0% to 15.5%. If, instead, 10% were fully statin intolerant, the use of ezetimibe (± statin ± PCSK9 inhibitor) increased from 32.7% to 38.5%, and the use of a PCSK9 inhibitor (+ ezetimibe ± statin) increased from 14.0% to 19.7%. In conclusion, in our simulation-based study, partial statin intolerance increased the need for nonstatins only modestly (by an absolute 2.2%), whereas having 10% of patients with full statin intolerance increased the need for PCSK9 inhibitors from 14% overall to approximately 20%." @default.
• W2912784612 created "2019-02-21" @default.
• W2912784612 creator A5001865596 @default.
• W2912784612 creator A5002862446 @default.
• W2912784612 creator A5026602252 @default.
• W2912784612 creator A5049964087 @default.
• W2912784612 creator A5056201514 @default.
• W2912784612 creator A5060465607 @default.
• W2912784612 creator A5075397090 @default.
• W2912784612 date "2019-04-01" @default.
• W2912784612 modified "2023-10-03" @default.
• W2912784612 title "Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease" @default.
• W2912784612 cites W1511974464 @default.
• W2912784612 cites W1520609538 @default.
• W2912784612 cites W2111099202 @default.
• W2912784612 cites W2133043280 @default.
• W2912784612 cites W2134159541 @default.
• W2912784612 cites W2530884669 @default.
• W2912784612 cites W2595226750 @default.
• W2912784612 cites W2605858734 @default.
• W2912784612 cites W2616658146 @default.
• W2912784612 cites W2740472173 @default.
• W2912784612 cites W2745511617 @default.
• W2912784612 cites W2751210700 @default.
• W2912784612 cites W2756234714 @default.
• W2912784612 cites W2766232664 @default.
• W2912784612 cites W2769002959 @default.
• W2912784612 cites W2769217183 @default.
• W2912784612 cites W2899997727 @default.
• W2912784612 cites W2901655499 @default.
• W2912784612 cites W4238580056 @default.
• W2912784612 cites W3025173419 @default.
• W2912784612 doi "https://doi.org/10.1016/j.amjcard.2019.01.028" @default.
• W2912784612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30736965" @default.
• W2912784612 hasPublicationYear "2019" @default.
• W2912784612 type Work @default.
• W2912784612 sameAs 2912784612 @default.
• W2912784612 citedByCount "10" @default.
• W2912784612 countsByYear W29127846122019 @default.
• W2912784612 countsByYear W29127846122020 @default.
• W2912784612 countsByYear W29127846122021 @default.
• W2912784612 countsByYear W29127846122022 @default.
• W2912784612 crossrefType "journal-article" @default.
• W2912784612 hasAuthorship W2912784612A5001865596 @default.
• W2912784612 hasAuthorship W2912784612A5002862446 @default.
• W2912784612 hasAuthorship W2912784612A5026602252 @default.
• W2912784612 hasAuthorship W2912784612A5049964087 @default.
• W2912784612 hasAuthorship W2912784612A5056201514 @default.
• W2912784612 hasAuthorship W2912784612A5060465607 @default.
• W2912784612 hasAuthorship W2912784612A5075397090 @default.
• W2912784612 hasBestOaLocation W29127846121 @default.
• W2912784612 hasConcept C126322002 @default.
• W2912784612 hasConcept C134018914 @default.
• W2912784612 hasConcept C2776839432 @default.
• W2912784612 hasConcept C2778114629 @default.
• W2912784612 hasConcept C2778163477 @default.
• W2912784612 hasConcept C2778657065 @default.
• W2912784612 hasConcept C2778824825 @default.
• W2912784612 hasConcept C2778849439 @default.
• W2912784612 hasConcept C2780072125 @default.
• W2912784612 hasConcept C2780745583 @default.
• W2912784612 hasConcept C2780948078 @default.
• W2912784612 hasConcept C2908647359 @default.
• W2912784612 hasConcept C43554185 @default.
• W2912784612 hasConcept C71924100 @default.
• W2912784612 hasConcept C90924648 @default.
• W2912784612 hasConcept C98274493 @default.
• W2912784612 hasConcept C99454951 @default.
• W2912784612 hasConceptScore W2912784612C126322002 @default.
• W2912784612 hasConceptScore W2912784612C134018914 @default.
• W2912784612 hasConceptScore W2912784612C2776839432 @default.
• W2912784612 hasConceptScore W2912784612C2778114629 @default.
• W2912784612 hasConceptScore W2912784612C2778163477 @default.
• W2912784612 hasConceptScore W2912784612C2778657065 @default.
• W2912784612 hasConceptScore W2912784612C2778824825 @default.
• W2912784612 hasConceptScore W2912784612C2778849439 @default.
• W2912784612 hasConceptScore W2912784612C2780072125 @default.
• W2912784612 hasConceptScore W2912784612C2780745583 @default.
• W2912784612 hasConceptScore W2912784612C2780948078 @default.
• W2912784612 hasConceptScore W2912784612C2908647359 @default.
• W2912784612 hasConceptScore W2912784612C43554185 @default.
• W2912784612 hasConceptScore W2912784612C71924100 @default.
• W2912784612 hasConceptScore W2912784612C90924648 @default.
• W2912784612 hasConceptScore W2912784612C98274493 @default.
• W2912784612 hasConceptScore W2912784612C99454951 @default.
• W2912784612 hasFunder F4320306257 @default.
• W2912784612 hasFunder F4320307105 @default.
• W2912784612 hasFunder F4320307115 @default.
• W2912784612 hasFunder F4320307765 @default.
• W2912784612 hasFunder F4320307770 @default.
• W2912784612 hasFunder F4320307776 @default.
• W2912784612 hasFunder F4320307781 @default.
• W2912784612 hasFunder F4320309056 @default.
• W2912784612 hasFunder F4320315666 @default.
• W2912784612 hasFunder F4320322352 @default.
• W2912784612 hasFunder F4320334790 @default.
• W2912784612 hasFunder F4320337449 @default.
• W2912784612 hasIssue "8" @default.

• next